As the primary component of the amyloid plaques seen in the brains of Alzheimer patients, amyloid- (A) refers to peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease. The amyloid precursor protein (APP), which is cut by specific enzymes to produce A, produces the peptides. Amyloid molecules can group together to create a variety of flexible, soluble oligomers.A amyloid-peptide buildup results from excessive A production or malfunctioning clearance mechanisms. Amyloid- forms diffuse and neuritic plaques in the parenchyma and blood vessels by self-aggregating into oligomers of various sizes. Strong synaptotoxins, proteasome inhibition, mitochondrial inhibition, alteration of intracellular Ca2+ levels, and induction of inflammatory processes are all characteristics of amyloid-oligomers and plaques. Neuronal dysfunction is also thought to be influenced by the loss of A's typical physiological functions.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71356 | Hoechst 34580 tetrahydrochloride (HOE 34580 tetrahydrochloride) | 2310135-08-9 | Hoechst 34580 tetra HCl is a marking dye from the Hoechst range. |
|
V97481 | Kayaflavone | 481-45-8 | Kayafavone is an aminoflavonoid biflavonoid. |
|
V96695 | Lecanemab (Mouse IGG2a) | Lecanemab (Mouse IGG2a) is a monoclonal antibody targeting soluble β-amyloid protein with the potential to alleviate cognitive decline. | |
|
V16894 | TRX-0237 mesylate | 1236208-20-0 | TRX-0237 mesylate (LMT-X; TRX0237;Leuco-MTx; LMTX; Hydromethylthionine mesylate), the mesylate salt ofTRX 0237 which is currentlyin phase III clinical trials by TauRx,is a 2nd-generation tau protein aggregation and TDP-43 aggregation inhibitor with the potential for the treatment of Alzheimers disease (AD) and frontotemporal dementia. |
|
V71418 | LPYFD-NH2 | 700361-48-4 | LPYFD-NH2 is a pentapeptide that can inhibit the aggregation of Aβ(1-42). |
|
V80619 | LPYFD-NH2 TFA | LPYFD-NH2 TFA is a pentapeptide that can inhibit the aggregation of Aβ(1-42). | |
|
V71420 | MCAAD-3 | 1625629-51-7 | MCAAD-3 is a near-infrared Aβ imaging probe with BBB (blood-brain barrier) penetration. |
|
V104231 | MeS-IMPY | 955376-42-8 | MeS-IMPY is a ligand for amyloid-β plaques. |
|
V71441 | Methyl tridecanoate | 1731-88-0 | Methyl tridecanoate moderately inhibits β-amyloid protein (β-amyloid) aggregation. |
|
V71367 | OAB-14 | 2140911-49-3 | OAB-14, a Bexarotene analogue, improves AD/Alzheimer's disease-related pathology and cognitive impairment by increasing beta-amyloid clearance in APP/PS1 mice. |
|
V71428 | p-HTAA | 1175142-38-7 | p-HTAA is a pentameric hydrothiopheneacetic acid. |
|
V98931 | Pep63 | 1781242-18-9 | Pep63 is a neuroprotective peptide (VFQVRARTVA). |
|
V71380 | PHF6 | 329897-62-3 | PHF6 (VQIVYK) is a self-assembly sequence that initiates aggregation of full-length tau protein and maps to the third microtubule-binding repeat region of tau protein. |
|
V87773 | PHF6 TFA | PHF6 (VQIVYK) TFA is a self-assembly sequence that initiates aggregation of full-length tau and is mapped to the third microtubule-binding repeat region of tau. | |
|
V87772 | QM-FN-SO3 ammonium | QM-FN-SO3 ammonium is a near-infrared (NIR) aggregation-induced emission (AIE) active probe that can penetrate the brain barrier. | |
|
V85737 | QP5020 | 3027434-06-3 | |
|
V85705 | QP5038 | 3031429-88-3 | |
|
V71386 | QR-0217 | 1027786-12-4 | QR-0217 is a potent Aβ1-40 aggregation inhibitor (antagonist) with IC50 of 7.5 µM. |
|
V76567 | RAGE antagonist peptide TFA | RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. | |
|
V70008 | RAGE/SERT-IN-1 | 2766739-35-7 | RAGE/SERT-IN-1 is a potent and orally bioactive inhibitor of advanced glycation end products (RAGE) and serotonin transporter (SERT) with IC50s of 8.26 μM and 31.09 nM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
